155 related articles for article (PubMed ID: 16946672)
1. Rethinking STOP-ROP: is it worthwhile trying to modulate excessive VEGF levels in prethreshold ROP eyes by systemic intervention? A review of the role of oxygen, light adaptation state, and anemia in prethreshold ROP.
Gaynon MW
Retina; 2006 Sep; 26(7 Suppl):S18-23. PubMed ID: 16946672
[TBL] [Abstract][Full Text] [Related]
2. Supplemental oxygen may decrease progression of prethreshold disease to threshold retinopathy of prematurity.
Gaynon MW; Stevenson DK; Sunshine P; Fleisher BE; Landers MB
J Perinatol; 1997; 17(6):434-8. PubMed ID: 9447528
[TBL] [Abstract][Full Text] [Related]
3. Prethreshold retinopathy of prematurity: VEGF inhibition without VEGF inhibitors.
Gaynon MW; Wong RJ; Stevenson DK; Sunshine P
J Perinatol; 2018 Oct; 38(10):1295-1300. PubMed ID: 30046180
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of myopia at 9 months in infants with high-risk prethreshold retinopathy of prematurity.
Davitt BV; Dobson V; Good WV; Hardy RJ; Quinn GE; Siatkowski RM; Summers CG; Tung B;
Ophthalmology; 2005 Sep; 112(9):1564-8. PubMed ID: 16023214
[TBL] [Abstract][Full Text] [Related]
5. Retinopathy of prematurity outcome in infants with prethreshold retinopathy of prematurity and oxygen saturation >94% in room air: the high oxygen percentage in retinopathy of prematurity study.
McGregor ML; Bremer DL; Cole C; McClead RE; Phelps DL; Fellows RR; Oden N;
Pediatrics; 2002 Sep; 110(3):540-4. PubMed ID: 12205257
[TBL] [Abstract][Full Text] [Related]
6. Association of systemic risk factors with the progression of laser-treated retinopathy of prematurity to retinal detachment.
Bourla DH; Gonzales CR; Valijan S; Yu F; Mango CW; Schwartz SD
Retina; 2008 Mar; 28(3 Suppl):S58-64. PubMed ID: 18317347
[TBL] [Abstract][Full Text] [Related]
7. Retinopathy of prematurity.
Chen J; Smith LE
Angiogenesis; 2007; 10(2):133-40. PubMed ID: 17332988
[TBL] [Abstract][Full Text] [Related]
8. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes.
Pediatrics; 2000 Feb; 105(2):295-310. PubMed ID: 10654946
[TBL] [Abstract][Full Text] [Related]
9. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity.
Sonmez K; Drenser KA; Capone A; Trese MT
Ophthalmology; 2008 Jun; 115(6):1065-1070.e1. PubMed ID: 18031819
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of retinopathy of prematurity.
Smith LE
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S140-4. PubMed ID: 15135797
[TBL] [Abstract][Full Text] [Related]
11. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study.
Good WV; Hardy RJ; Dobson V; Palmer EA; Phelps DL; Quintos M; Tung B;
Pediatrics; 2005 Jul; 116(1):15-23. PubMed ID: 15995025
[TBL] [Abstract][Full Text] [Related]
12. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity.
Pieh C; Agostini H; Buschbeck C; Krüger M; Schulte-Mönting J; Zirrgiebel U; Drevs J; Lagrèze WA
Br J Ophthalmol; 2008 May; 92(5):689-93. PubMed ID: 18408080
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of vascular endothelial growth factor and angiopoietin 2 in retinopathy of prematurity.
Bányász I; Bokodi G; Vannay A; Szebeni B; Treszl A; Vásárhelyi B; Tulassay T; Szabó A
Curr Eye Res; 2006; 31(7-8):685-90. PubMed ID: 16877277
[TBL] [Abstract][Full Text] [Related]
14. Risk analysis of prethreshold retinopathy of prematurity.
Hardy RJ; Palmer EA; Dobson V; Summers CG; Phelps DL; Quinn GE; Good WV; Tung B;
Arch Ophthalmol; 2003 Dec; 121(12):1697-701. PubMed ID: 14662587
[TBL] [Abstract][Full Text] [Related]
15. [The prognostic significance of shape of demarcation line and ridge in clinical course of active phase of retinopathy of prematurity].
Ciechan J; Gerkowicz M; Wróblewska E
Klin Oczna; 2003; 105(6):392-4. PubMed ID: 15049262
[TBL] [Abstract][Full Text] [Related]
16. [Are there predictors for proliferative retinopathy of prematurity and is supplemental oxygen a useful conservative treatment option?].
Müller H; Weiss C; Kuntz S; Akkoyun I; Schaible T
Klin Padiatr; 2005; 217(2):53-60. PubMed ID: 15770574
[TBL] [Abstract][Full Text] [Related]
17. The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge.
Cavallaro G; Filippi L; Bagnoli P; La Marca G; Cristofori G; Raffaeli G; Padrini L; Araimo G; Fumagalli M; Groppo M; Dal Monte M; Osnaghi S; Fiorini P; Mosca F
Acta Ophthalmol; 2014 Feb; 92(1):2-20. PubMed ID: 23617889
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity.
Sato T; Kusaka S; Shimojo H; Fujikado T
Ophthalmology; 2009 Nov; 116(11):2165-9. PubMed ID: 19700197
[TBL] [Abstract][Full Text] [Related]
19. Multicenter trial of early treatment for retinopathy of prematurity: study design.
Hardy RJ; Good WV; Dobson V; Palmer EA; Phelps DL; Quintos M; Tung B;
Control Clin Trials; 2004 Jun; 25(3):311-25. PubMed ID: 15157731
[TBL] [Abstract][Full Text] [Related]
20. [Epidemiology and pathophysiology of retinopathy of prematurity].
Kermorvant-Duchemin E; Sennlaub F; Behar-Cohen F; Chemtob S
Arch Pediatr; 2011 Jul; 18 Suppl 2():S79-85. PubMed ID: 21763979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
